Nutrition 21, Inc., Purchase, NY, has received an exclusive license in the U.S. from Denmark-based Provita Development ApS for Coldizin, an ingredient combination patented in the U.S. and Europe for enhancing upper-respiratory health.

A patent is pending in Canada. The exclusive license allows Nutrition 21 to expand its product portfolio with a novel, clinically substantiated ingredient for the $4.5 billion U.S. cough and cold category.

“Coldizin is a clinically substantiated product that shows significant results in helping people deal with upper respiratory symptoms. Its innovative blend of the bioflavonoid troxerutin and zinc provides an option for either the dietary supplement or homeopathic segments,” said William Levi, vice president, Ingredients and Special Markets.

Carsten Waern, CEO and chairman of Provita said, “We are excited to have a professional partner in Nutrition 21, who understands the North American marketplace and is a well-established, credible player in the industry. They have an excellent history of selling and marketing value-added and clinically substantiated ingredients. We look forward to a mutually successful, long-term partnership.”